Medicare Part D coverage · carbidopa · RxCUI 308989
carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet
Per the CMS 2026 Part D formulary file, carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet is covered by 5,052 Medicare Part D plans (100% of enrollable products), averaging Tier 2.1, with prior authorization required on 0% of covering formularies.
- 100%
- Plan coverage
- 5,052
- Plans covering
- T2.1
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet
Per the CMS 2026 Part D formulary file, carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet (RxNorm concept RXCUI 308989, generic name carbidopa) appears on 328 distinct formulary files spanning 5,052 Medicare Part D plan offerings - 100% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.1.
Real-world access to carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0.6% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,842 Part D beneficiaries filled carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet in 2023, with total plan-and-beneficiary spending of $8,583,589 and an average per-beneficiary annual cost of $1,772.74. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet today.
Coverage Details
- Formularies covering
- 328
- Plans covering
- 5,052
- Coverage rate
- 100%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0.6% of formularies
2023 Medicare Spending
- Beneficiaries
- 4,842
- Total spending
- $8,583,589
- Avg per beneficiary
- $1,772.74
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T1 | No | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T1 | No | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T1 | No | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T1 | No | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T1 | No | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T1 | No | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T1 | No | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T1 | No | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T1 | No | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T1 | No | $0 | VA |
| AARP Medicare Advantage from UHC AL-0001 (HMO-POS) | Unitedhealthcare OF THE Midlands, Inc. | T1 | No | $0 | AL |
| AARP Medicare Advantage from UHC CA-0002 (HMO-POS) | UHC OF California | T1 | No | $0 | CA |
| UHC Sharp Medicare Advantage CA-001P (HMO-POS) | UHC OF California | T1 | No | $0 | CA |
| AARP Medicare Advantage from UHC CA-003P (HMO-POS) | UHC OF California | T1 | No | $0 | CA |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet covered by Medicare Part D?
Yes, carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet is covered by 5,052 Medicare Part D plans (100% of all Part D formularies).
What tier is carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet on Medicare Part D plans?
carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet averages Tier 2.1 across Part D plans, ranging from Tier 1 to Tier 4.
Does carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet. Step therapy: 0%. Quantity limits: 0.6%.
How much does Medicare spend on carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet?
In 2023, total Medicare Part D spending on carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet was $8,583,589, covering 4,842 beneficiaries. The average spend per beneficiary was $1,772.74.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- amantadine hydrochloride 100 MG Oral Capsule T2.1
- testosterone cypionate 200 MG/ML Injectable Solution T2.1
- 24 HR propranolol hydrochloride 160 MG Extended Release Oral Capsule T2.1
- flurbiprofen sodium 0.3 MG/ML Ophthalmic Solution T2.1
- {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack [Apri 28 Day] T2.1
- {21 (desogestrel 0.15 MG / ethinyl estradiol 0.03 MG Oral Tablet) / 7 (inert ingredients 1 MG Oral Tablet) } Pack [Reclipsen 28 Day] T2.1
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA